Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Barclays PLC

Barclays PLC decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 489,056 shares of the medical equipment provider’s stock after selling 34,741 shares during the quarter. Barclays PLC owned about 0.25% of Zimmer Biomet worth $48,172,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Legacy Wealth Asset Management LLC boosted its holdings in shares of Zimmer Biomet by 2.3% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 106 shares during the last quarter. Global Retirement Partners LLC lifted its position in Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 111 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Generali Asset Management SPA SGR boosted its holdings in Zimmer Biomet by 0.9% in the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after purchasing an additional 122 shares during the last quarter. Finally, Brookstone Capital Management grew its position in Zimmer Biomet by 1.3% during the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after purchasing an additional 123 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Robert W. Baird reiterated a “neutral” rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a report on Friday, January 9th. Finally, Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Down 0.9%

Zimmer Biomet stock opened at $93.22 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock has a market capitalization of $18.24 billion, a PE ratio of 26.33, a price-to-earnings-growth ratio of 1.92 and a beta of 0.58. The business has a 50 day simple moving average of $92.19 and a 200-day simple moving average of $95.52. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter last year, the company earned $2.31 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.